NASDAQ · Biotechnology · USD
Rezolute, Inc. (RZLT) Stock Analysis
Rezolute, Inc. (RZLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RZLT Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.70
- Previous Close
- $3.70
- Day's Range
- 3.65–3.79
- 52-Week Range
- 1.07–11.46
- Volume
- 929.38K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.54
Valuation
- Market Cap
- $357.87M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.75
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$74.41M
- Shares Outstanding
- 96.72M
- 1-Year Return
- −58.24%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 1.50M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RZLT closed at $3.70, −58.24% over 1 year.
Rezolute, Inc. (RZLT) has a market capitalization of $357.87M.
In fiscal 2025, RZLT reported revenue of $0.00.
RZLT Stock Return by Calendar Year
Rezolute, Inc. (RZLT) 10-year return: what $10,000 became
- 1 year
- $10,000 $4,176
- −58.24%
- 5 years
- $10,000 $5,692
- −43.08%
- 10 years
- $10,000 $529
- −94.71%
If you had invested $10,000 in Rezolute, Inc. (RZLT) 10 years ago, at the close on October 21, 2016, it would have been worth $529 at the close on October 21, 2026: −94.71% in total, −25.47% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +56.78% |
| 2025 | −51.84% |
| 2024 | +393.45% |
| 2023 | −52.03% |
| 2022 | −56.69% |
| 2021 | −60.13% |
| 2020 | +108.52% |
| 2019 | +27.78% |
| 2018 | −89.83% |
| 2017 | −11.50% |
| 2016 (partial year) | +16.96% |
As of October 21, 2026.
RZLT Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$74.41M | — |
| 2024 | $0.00 | −$68.46M | — |
| 2023 | $0.00 | −$51.79M | — |
| 2022 | $0.00 | −$41.06M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$79.89M | −$74.41M | — |
| 2024 | $0.00 | — | −$70.42M | −$68.46M | — |
| 2023 | $0.00 | — | −$55.99M | −$51.79M | — |
| 2022 | $0.00 | — | −$41.61M | −$41.06M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
Recent News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
YahooRezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026
BenzingaLake Street Maintains Buy on Rezolute, Raises Price Target to $12
BenzingaCitizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
BenzingaCantor Fitzgerald Upgrades Rezolute to Overweight
BenzingaRezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
Stocktwits
All 19 articles ↓Show fewer ↑
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
YahooFDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints
BenzingaRezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
YahooRezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment.
BenzingaLake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9
BenzingaCraig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7
BenzingaHC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10
BenzingaRezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
YahooRezolute Q4 EPS $(0.20) Misses $(0.15) Estimate
BenzingaRezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset
SeekingAlphaRezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
InvestorsHubRezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
YahooRezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B